Skip to main content

Advertisement

  • Case report
  • Open Access
  • Open Peer Review

Radiation-induced chondrosarcoma of the scapula after radiotherapy for lung cancer: a case report and review of the literature

  • 1,
  • 1,
  • 2,
  • 3,
  • 4 and
  • 5Email author
Journal of Medical Case Reports201812:57

https://doi.org/10.1186/s13256-018-1606-2

  • Received: 20 September 2017
  • Accepted: 6 February 2018
  • Published:
Open Peer Review reports

Abstract

Background

Radiotherapy associated with chemotherapy is a well-established treatment modality for locally advanced non-small cell lung cancers. Radiation-induced second malignancies, particularly radiation-induced sarcomas, are rare. Some authors reported a recent increase in the incidence of this rare complication, especially because of the improved prognosis and survival of patients after radiotherapy. Pathogenic mechanisms of radiation-induced sarcomas are poorly understood. However, diagnosis criteria are well established. Treatment options must be discussed and adapted to the patient’s profile. Surgery in irradiated tissue is challenging, with limited treatment options with chemotherapy and radiotherapy.

Case presentation

We report the case of a 62-year-old Moroccan man diagnosed as having chondrosarcoma of his right scapula, who was irradiated 10 years ago for stage IIIB non-small cell lung cancer. This case was managed by a complete resection of the tumor with good functional and oncological outcomes. To the best of our knowledge, the scapular location of radiation-induced sarcoma after irradiation for lung cancer has never been described in the literature.

Conclusion

Radiation-induced sarcoma of the scapula represents a rare situation that must be actively researched to have access to an optimal therapeutic approach.

Keywords

  • Radiotherapy
  • Sarcomas
  • Scapula
  • Chondrosarcoma

Background

Radiation therapy (RT) plays a significant role in the management of thoracic tumors [1]. Most of these tumors require RT as a local measure for definitive treatment of medically inoperable or surgically unresectable disease, or as part of a multimodality regimen for locally advanced disease [1, 2]. The standard care for stage III unresectable disease is combined chemoradiotherapy [1, 2].

The occurrence of radiation-induced sarcoma (RIS) in the scapula after RT for lung cancer is a very rare complication [3]. With improved oncologic outcomes, post-irradiation sarcomas are increasingly seen in long-term survivors with an estimated risk of up to 0.3% [4]. The spectrum of radiation-induced tumors includes soft tissue sarcoma, osteosarcoma, squamous cell carcinoma (SCC), leukemia, and neuroendocrine carcinomas, which may develop in the head and neck, esophagus, lung, or stomach [5]. We report here a case of chondrosarcoma of the right scapula occurring 10 years after completion of chemoradiotherapy for stage IIIB SCC developed in the upper lobe of the right lung.

Case presentation

A 62-year-old Moroccan man, retired from the army, married, father of five children, a chronic tobacco smoker who did not consume alcohol, without any medical history, underwent concomitant chemoradiation for stage IIIB SCC of his right lung in 2007 (Fig. 1). The protocol included radiotherapy using gamma photons of 1.25 Mv energy, delivered at a total dose of 60 Gy, 2 Gy by fraction, in 6 weeks, with two opposed fields including the right scapula. In combination with the RT we used chemotherapy according to the vinorelbine-cisplatin regimen: vinorelbine 25 mg/m2 day 1 and 8; cisplatin 75 mg/m2 day 1 repeated every 3 weeks until the end of RT. A total of three cycles was delivered. Following this therapy he was in good health, his regular follow-up evaluations did not reveal any notable pathologic findings, and he did not need to take any specific medication. However, 10 years later he presented a right scapula pain. He stopped smoking tobacco in 2007, and suffered from right scapula pain for 3 months. On admission his temperature was 37.5, his pulse 90 beats per minute, and his blood pressure 135/75 mmHg. A clinical examination found a fixed, sensitive right scapular mass that measured 10 cm at its big axis (Fig. 2). A neurologic examination showed a conscious patient well oriented with preserved memory. A cranial nerve examination showed no disturbance in olfaction or in visual fields. Ocular motricity is well conserved as well as facial sensation and motricity. The rest of the cranial nerve examination did not reveal any dysarthria, hearing loss, tongue weakness, or neck weakness. Motricity of arms and inferior members was well conserved without any involuntary movements. Muscular force was preserved as well as sensitivity (light touch, temperature, vibration, joint position sense). He suffered from a slight neuropathic pain of his right arm whose intensity was estimated to be 4/10 according to the visual analogue scale. Biceps, triceps, brachioradialis, knee (patellar), and ankle (Achilles) reflexes did not reveal any abnormalities. A chest computed tomography (CT) scan showed a tumor process on his right scapula, with sequela lung injury in the territory of the first tumor (Fig. 3). Magnetic resonance imaging (MRI) of the scapular region showed malignant tumor process centered on the supraspinous and infraspinous muscles with hyposignal at T1 and heterogeneous hypersignal at T2 measuring 90 mm on the longest axis and 60 mm on the shortest axis. There was no involvement of his right shoulder joint (Fig. 4). Data from a bone scintigraphy were in favor of a hyperfixation focus at the right scapula (Fig. 5). A single-photon emission computed tomography (SPECT)-CT examination showed an osteocondensing and lytic aspect in the spine of his right scapula (Fig. 6). Laboratory tests did not reveal any abnormalities, showing good liver and renal functions. A surgical biopsy of the tumor was performed. Histopathological examination showed a grade 1 chondrosarcoma (Fig. 7). An extension assessment, including CT of his chest and abdominal ultrasonography, did not find distant metastasis. After a multidisciplinary staff meeting a surgical resection was performed with safe margins. The surgical procedure consisted of a resection of his right scapula, with fixation of his right arm thanks to osteosynthesis equipment. No adjuvant treatment was necessary because of the free margins after surgery and the low grade of the chondrosarcoma. A follow-up at 6 months (clinical examination and CT scan) did not show any sign of recurrence or specific complication.
Fig. 1
Fig. 1

Scannographic cut showing a mediastinopulmonary process stage IIIB

Fig. 2
Fig. 2

Right scapular mass

Fig. 3
Fig. 3

Chest computed tomography scan showing a tumor process on the right scapula

Fig. 4
Fig. 4

Magnetic resonance imaging of the scapular region with malignant tumor process centered on the supraspinous and infraspinous muscles

Fig. 5
Fig. 5

Bone scintigraphy with hyperfixation focus at the right scapula

Fig. 6
Fig. 6

Single-photon emission computed tomography-computed tomography with osteocondensing and lytic aspect in the spine of the right scapula

Fig. 7
Fig. 7

Histopathological examination of the biopsy in favor of grade 1 chondrosarcoma

Discussion

This is a rare case of radiation-induced chondrosarcoma, occurring 10 years after chemoradiation for non-small cell lung cancer (NSCLC). RIS after chemoradiation for lung cancer is a very rare complication. The rarity of this situation is due to the poor prognosis of advanced stage of NSCLC with limited survival, which exceptionally exceeds 3 years [1].

The carcinogenic effects of ionizing radiation have been described in several publications [5]. The real mechanisms in radiation-induced tumor genesis remain poorly known [6]. In a published series, their frequency varies between 0.15 and 0.75% [5, 6]. Phillips and Sheline estimated the frequency of sarcomas after irradiation for breast cancer to be 0.23% [6]. Mark et al. estimated the absolute risk of developing RIS to be from 0.03 to 0.8% after RT for gynecologic malignancies [7]. Amendola et al. noted an estimated incidence of sarcomas of 0.09 to 0.11% after radiotherapy for any purpose [6]. Furthermore, Huvos et al. and Souba et al. estimated that 5% of sarcomas developed after therapeutic or accidental irradiation [4]. All tissue types can be processed by irradiation, although the radio sensitivity varies with the type of irradiated organ [8]. There is no histological evidence to confirm the origin of radiation-induced tumors [9]. Ionizing radiation causes damage to healthy tissue included in the radiation field. Some authors identified the specific mesenchymal stem cells that can regenerate on injury [7, 9]. On irradiation-induced injury, the stem cells rapidly start proliferating and can regenerate injured tumoral tissue [7].

Several risk factors are probably implicated in influencing the occurrence of these secondary tumors. The radiation dose which is a variable parameter depending on the irradiated organs, the type of chemotherapy that can potentiate the effect of RT, young age (children are especially sensitive to radiation oncogenesis), and a genetic predisposition to multiple tumors [9, 10]. Young age exposure seems to be an important risk factor, especially in tumors with a good prognosis such as hematologic malignancies [10]. Relative risk (RR) of second solid cancer at high-dose sites for radiotherapy in lung cancer is different depending on the period of latency. For latency between 5 and 9 years the RR is estimated to be 1.12 (0.98–1.27), between 10 and 14 years it is estimated to be 1.37 (1.12–1.65), and after 15 years of latency the RR is estimated to be 1.62 (1.23–2.09) with p-trend at 0.0079 [11]. There are no clear data reporting eventual implication of concurrent chemotherapy in the carcinogenesis of RIS.

Diagnosis

The diagnosis is established by criteria established by Cahan et al. in 1948 [12] and revised by Murray et al. in 1999 [13]. A history of radiotherapy for cancer, an asymptomatic latency period of several years, the occurrence of tumor in the irradiation field, and histological evidence of the secondary tumor [12]. Complete remission of the primary tumor is also necessary to establish this diagnosis [9]. Our case meets the criteria of Murray et al. for RIS [13]. They specify that radiotherapy must have been administered previously and that the sarcoma must have developed from an area within the 5% isodose line [14]. To the best of our knowledge, radiation-induced scapular chondrosarcoma has not been described previously. The rarity of radiation-induced chondrosarcoma is reflected by the very few case series that have included such cases. In fact, in a multi-institutional series of 80 histologically confirmed cases that were diagnosed as RIS between 1975 and 1995, only one patient had chondrosarcoma [14]. Some reviews reported a large predominance of osteosarcomas and fibrosarcomas in RIS of the chest wall [11].

Management

Therapeutic approaches are often limited. Surgery is the only curative method, when it is possible. The difficulty of surgery in irradiated areas is known, but must be seriously considered if the tumor is diagnosed at an early stage and if the surgeon is experienced. In advanced stages, chemotherapy may have a place, despite poor tumor response in irradiated areas [15]. In these cases the prognosis is also poor, and median survival does not exceed a few months. The use of new irradiation procedures reducing the field of exposure should allow a clear decrease in the incidence of RIS [15].

Conclusions

This case is about a very rare situation, radiation-induced chondrosarcoma of the right scapula. This event is very uncommon making it almost impossible to perform prospective clinical trials specifically designed to compare different treatment approaches. Surgery is the principal method of treatment. A close follow-up of irradiated patients is the only way for an early diagnosis of this serious complication.

Declarations

Acknowledgements

We sincerely thank Mrs Souad TADLAOUI for her assistance.

Funding

Not applicable.

Availability of data and materials

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Authors’ contributions

All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Thoracic surgery, Ibn Sina Military Hospital, Faculty of Medicine and Pharmacy Mohamed VI, Caddy Ayyad University, Marrakesh, Morocco
(2)
General Surgery, Ibn Sina Military Hospital, Faculty of Medicine and Pharmacy Mohamed VI, Caddy Ayyad University, Marrakesh, Morocco
(3)
Radiation Oncology, Mohammed V Military Hospital, Faculty of Medicine and Pharmacy Mohamed VI, Caddy Ayyad University, Marrakesh, Morocco
(4)
Anatomopathology, Ibn Sina Military Hospital, Faculty of Medicine and Pharmacy Mohamed VI, Caddy Ayyad University, Marrakesh, Morocco
(5)
Medical Oncology, Ibn Sina Military Hospital, Faculty of Medicine and Pharmacy Mohamed VI, Caddy Ayyad University, Marrakesh, Morocco

References

  1. Antoni D, Mornex F. Chemoradiotherapy of locally advanced nonsmall cell lung cancer: state of the art and perspectives. Curr Opin Oncol. 2016;28:104–9.View ArticlePubMedGoogle Scholar
  2. Burdett SS, Stewart LA, Rydzewska L. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane Database Syst Rev. 2007;3:CD006157.Google Scholar
  3. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.View ArticlePubMedGoogle Scholar
  4. Huvos AG, Woodard HQ, Cahan WG, Higinbotham NL, Stewart FW, Butler A, Bretsky SS. Postradiation osteogenic sarcoma of bone and soft tissues. A clinicopathologic study of 66 patients. Cancer. 1985;55:1244–55.View ArticlePubMedGoogle Scholar
  5. Berrington de Gonzalez A, Gilbert E, Curtis R, Inskip P, Kleinerman R, Morton L, Rajaraman P, Little MP. Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. Int J Radiat Oncol Biol Phys. 2013;86:224–33.View ArticlePubMedGoogle Scholar
  6. Amendola BE, Amendola MA, McClatchey KD, Miller CH Jr. Radiation-associated sarcoma: a review of 23 patients with postradiation sarcoma over a 50-year period. Am J Clin Oncol. 1989;12(5):411–5.View ArticlePubMedGoogle Scholar
  7. Mark RJ, Poen J, Tran LM, Fu YS, Selch MT, Parker RG. Postirradiation sarcomas. A single-institution study and review of the literature. Cancer. 1994;73(10):2653–62.View ArticlePubMedGoogle Scholar
  8. Kirova Y, Vilcoq JR, Asselain B, Sastre-Garau X, Campana F, Dendale R, Bollet M, Fourquet A. Sarcomes radioinduits après cancer du sein : expérience de l’institut Curie et revue de la littérature. Cancer Radiother. 2006;10:83–90.View ArticlePubMedGoogle Scholar
  9. Sigurdson AJ, Irene MJ. Second cancer after radiotherapy: any evidence for radiation-induced genomic instability? Oncogene. 2003;22:7018–27.View ArticlePubMedGoogle Scholar
  10. Chauveinc L, Lefevre S, Malfoy B, Dutrillaux B. Actualités sur les tumeurs radio-induites : les études génétiques. Bull Cancer. 2002;89:181–96.PubMedGoogle Scholar
  11. de Gonzalez AB, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, Stovall M, Ron E. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011;12:353–60.View ArticlePubMed CentralGoogle Scholar
  12. Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL. Sarcoma arising in irradiated bone: report of eleven cases. Cancer. 1948;1:3–29.View ArticlePubMedGoogle Scholar
  13. Murray EM, Werner D, Greeff EA, Taylor DA. Postradiation sarcomas: 20 cases and a literature review. Int J Radiat Oncol Biol Phys. 1999;45(4):951–61.View ArticlePubMedGoogle Scholar
  14. Chapelier AR, Bacha EA, de Montpreville VT, et al. Radical resection of radiation-induced sarcoma of the chest wall: report of 15 cases. Ann Thorac Surg. 1997;63(1):214–9.View ArticlePubMedGoogle Scholar
  15. Obid P, Vierbuchen M, Wolf E, Reichl M, Niemeyer T, Übeyli H, Richter A. Radiation-Induced Intraspinal Chondrosarcoma: A Case Report. Glob Spine J. 2015;5(5):e74–7. https://doi.org/10.1055/s-0035-1546953. ISSN 2192-5682.View ArticleGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement